Myeloproliferative neoplasms (MPNs) are a group of three related blood cancers in which the bone marrow overproduces one of the three cellular components of blood (erythrocytes, leukocytes and platelets). Over 3200 patients in the UK are diagnosed with MPNs every year. A common cause of MPNs is a mutation in a protein called Janus kinase 2 (termed VF-JAK2) that makes it permanently active, resulting in excessive blood clotting or bleeding. As these defects severely reduce the quality of life and life expectancy of patients with VF-JAK2 MPNs, it is critical that they are effectively treated. Our research suggests that drugs currently used to treat type 2 diabetes offer a new approach to reduce bleeding and clotting complications in patients with MPNs. To test this hypothesis, the student will use cutting-edge biochemical and genetic approaches to validate and characterise signalling pathway regulation and function involved in dysfunctional inflammation and haemostatic responses in vascular endothelial cells from MPN patients.
This is a full time PhD in Medical Sciences.
For informal inquiries, please contact Professor Tim Palmer ([email protected]
Location and Research Culture
Hull York Medical School’s unique partnership brings together the expertise of both the Universities of Hull and York and offers a thriving environment in which to conduct world-leading research. Strong partnerships with NHS Trusts and community health organisations offer a wide clinical base within which to study those conditions which most affect our communities – improving their health while developing research work that can be applied nationally and globally.
The School’s academic and clinical researchers at have a strong reputation for their work, 85% of which is classed as ‘world-leading’ or ‘internationally excellent’ (REF 2014). Their research is advancing improvements in healthcare – treatment, diagnosis and care – improving the health of people locally and impacting national and international health agendas.
The student will join a dynamic research team and thriving community of graduate students from the UK and overseas in the Centre for Atherothrombosis and Metabolic Disease at the University of Hull. Many students also study in our laboratories at local hospitals across the city. This gives our students unparalleled access to the facilities, academic and clinical expertise to thrive in their research.
Professor Tim Palmer, Chair of Cardiovascular Biology and Director of the Centre for Atherothrombosis and Metabolic Disease. Email: [email protected]
Co-supervisor: Dr. David Allsup, Senior Lecturer in Haematology.
To be arranged upon acceptance of an offer.
In order to qualify for this position, you will require an undergraduate degree with at least a 2.1, or equivalent, in a relevant subject (Biochemistry, Molecular and Cellular Biology, Pharmacology, Pharmacy or related discipline). English Language IELTS 6.5 with a minimum of 6.0 in each component.
How to Apply
All applications MUST be submitted through the HYMS Postgraduate Centre via the online application system: https://www.york.ac.uk/study/postgraduate/courses/apply?course=DRPMEDSMED3&level=postgraduate
To apply for a “PhD in Medical Sciences” at Hull York Medical School, please quote HYMS with the project title when applying. In order for the Panel to get a sense of your academic background, commitment and interest, you are required to complete the application form in full and provide a research proposal/outline of academic interest. Research proposals and personal statements may be used in selecting applicants for interview. If you have any queries on how to apply, please email [email protected]
Applicants who are shortlisted for interview will be sent details of the date, time and venue via email. If you are not invited for interview, it means that your application has not been successful. Please note that we do not offer feedback to applicants who are not invited to the interview.